Skip to content

AMGN

Amgen Inc.

Revenue by product

2025, ended Dec 31, 2025

Earlier:

Products by fiscal year

Products by fiscal year
Line, in USD20252024202320222021202020192018201720162015201420132012201120102009
Product sales35.1B32.0B26.9B24.8B——22.2B——————————
Other products
7.26B5.63B4.70B5.05B5.71B5.37B4.74B5.57B2.58B3.16B———————
Repatha
3.02B2.22B1.64B1.30B1.12B0.89B0.66B0.55B—————————
Evenity
2.10B1.56B1.16B0.79B0.53B0.35B———————————
Prolia
4.41B4.37B4.05B3.63B3.25B2.76B2.67B2.29B1.97B1.64B————0.20B——
Enbrel
2.23B3.32B3.70B4.12B4.47B5.00B5.23B5.01B5.43B5.97B————3.70B—3.49B
Tezspire
1.48B0.97B0.57B0.17B—————————————
Tepezza
1.90B1.85B0.45B——————————————
Blincyto
1.56B1.22B0.86B0.58B0.47B————————————
Otezla
2.27B2.13B2.19B2.29B2.25B2.20B0.18B——————————
Nplate
1.52B1.46B1.48B1.31B1.03B0.85B0.80B———————0.30B—0.11B
Krystexxa
1.34B1.19B0.27B——————————————
Vectibix
1.18B1.05B0.98B0.89B0.87B—————————0.32B—0.23B
Kyprolis
1.41B1.50B1.40B1.25B1.11B1.07B1.04B0.97B0.84B————————
Aranesp
1.39B1.34B1.36B1.42B1.48B1.57B1.73B1.88B2.05B2.09B————2.30B—2.65B
Xgeva
2.08B2.23B2.11B2.01B2.02B1.90B1.94B1.79B1.58B1.53B————0.35B——
Neulasta (pegfilgrastim)
—————2.29B3.22B4.48B4.53B4.65B————3.95B—3.36B
Other revenues1.60B1.40B1.28B1.52B1.68B1.18B1.16B1.21B1.05B————————
————————2.81B3.96B————4.17B—4.51B
Total36.8B33.4B28.2B26.3B26.0B25.4B23.4B23.7B22.8B23.0B21.7B20.1B18.7B17.3B15.3B15.1B14.4B

A period with only a total isn't split by product in the filings.